Search - tctmd.com

Displaying 261 - 280 of 511

Sort: Relevancy | Date

News Daily News

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Yael L. Maxwell

June 03, 2015

News Daily News

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

Yael L. Maxwell

June 03, 2015

News Conference News EuroPCR 2015

Sapien 3 Experience in Europe, Canada Shows Low Mortality, Paravalvular Leak at 30 Days

Yael L. Maxwell

May 21, 2015

News Industry News

First One-Year Report Of Outcomes With Edwards SAPIEN 3 Valve Demonstrate High Survival And Low Stroke Rate

May 19, 2015

News Daily News

FRANCE 2: Prior CABG Does Not Influence Mortality After TAVR

Todd Neale

May 18, 2015

News Daily News

FRANCE 2: Los Antecedentes de CABG No Influyen en la Mortalidad Post-TAVR

Todd Neale

May 18, 2015

News Daily News

Los Delirios son Frecuentes tras la Sustitución de la Válvula Aórtica y se asocian a una Mayor Mortalidad

Todd Neale

May 04, 2015

News Daily News

Un Estudio Informa sobre la Embolización Cerebral Durante la Realización de TAVR

April 29, 2015

News Daily News

Study Provides Insight Into Cerebral Embolization During TAVR

April 29, 2015

News Daily News

After Propensity Matching, Early Mortality Risk Still Evident for Transapical TAVR

Todd Neale

April 10, 2015

News Daily News

随着TAVR的发展，局部麻醉可以作为低风险患者的一个选项

Yael L. Maxwell

April 03, 2015

News Daily News

As TAVR Evolves, Local Anesthesia Could Be an Option for Lower-Risk Patients

Yael L. Maxwell

April 03, 2015

News Daily News

A medida que va Evolucionando la TAVR, la Anestesia Local podría ser una Opción en Pacientes de Bajo Riesgo

Yael L. Maxwell

April 03, 2015

News Industry News

Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures

March 31, 2015

News Industry News

Medtronic Announces Japanese Regulatory Approval of CoreValve® System

March 30, 2015

News Daily News

PARTNER at 5 Years: TAVR Shows Durable Benefit in Inoperable Patients

March 25, 2015

News Industry News

Medtronic CoreValve® Evolut(TM) R System Yields Exceptional Outcomes in First Clinical Study

March 16, 2015

News Conference News ACC 2015

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Yael L. Maxwell

March 15, 2015

News Industry News

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

Advertisement

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

Sapien 3 Experience in Europe, Canada Shows Low Mortality, Paravalvular Leak at 30 Days

First One-Year Report Of Outcomes With Edwards SAPIEN 3 Valve Demonstrate High Survival And Low Stroke Rate

FRANCE 2: Prior CABG Does Not Influence Mortality After TAVR

FRANCE 2: Los Antecedentes de CABG No Influyen en la Mortalidad Post-TAVR

Los Delirios son Frecuentes tras la Sustitución de la Válvula Aórtica y se asocian a una Mayor Mortalidad

Un Estudio Informa sobre la Embolización Cerebral Durante la Realización de TAVR

Study Provides Insight Into Cerebral Embolization During TAVR

After Propensity Matching, Early Mortality Risk Still Evident for Transapical TAVR

随着TAVR的发展，局部麻醉可以作为低风险患者的一个选项

As TAVR Evolves, Local Anesthesia Could Be an Option for Lower-Risk Patients

A medida que va Evolucionando la TAVR, la Anestesia Local podría ser una Opción en Pacientes de Bajo Riesgo

Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures

Medtronic Announces Japanese Regulatory Approval of CoreValve® System

PARTNER at 5 Years: TAVR Shows Durable Benefit in Inoperable Patients

Medtronic CoreValve® Evolut(TM) R System Yields Exceptional Outcomes in First Clinical Study

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content